Heparin Shortage: What Providers and Prescribers Need to Know in 2026

Unfractionated heparin (UFH) has been on the FDA drug shortage list continuously since November 2017. In 2026, the supply situation continues to evolve, with significant formulation-specific disruptions that directly affect inpatient and outpatient prescribing. This briefing provides an evidence-based summary of current supply conditions, clinical implications, substitution guidance, and practical tools to support patient access.

Current Supply Status by Manufacturer (2026)

Based on the most recent ASHP drug shortage database updates:

Pfizer: Shortage attributed to increased demand and manufacturing delays. 1,000 unit/mL 10 mL and 30 mL vials and 5,000 unit/mL 1 mL and 10 mL vials temporarily discontinued. 5,000 unit/mL Carpuject syringes on backorder; 10,000 unit/mL 0.5 mL Carpuject in limited supply with weekly releases. Additionally, Pfizer issued a Drug Warning Letter regarding a potential molding defect on the needle sheath tip of certain Carpuject units — review the Pfizer advisory for inspection guidance.

Sagent: 1,000 unit/mL 10 mL vials on backorder (April 2026 estimated); 1,000 unit/mL 30 mL vials on limited allocation.

Techdow USA: 10,000 units/mL 1 mL vials and 20,000 units/mL 1 mL vials on backorder, no estimated release date.

Mylan (Viatris): Permanently discontinued all heparin injection products (March–April 2025). Do not expect return.

Fresenius Kabi and Hikma: Currently the most consistently available manufacturers across multiple formulations and strengths. Recommend directing procurement teams to prioritize these suppliers.

Root Cause Analysis: Why This Shortage Persists

The heparin shortage is structural, not episodic. Key factors include: (1) biological sourcing from porcine intestinal mucosa, with ~60% of U.S. supply derived from Chinese-sourced pig tissue; (2) a complex, capital-intensive extraction and purification process that cannot be rapidly scaled; (3) high, inelastic demand — some estimates suggest 50–70% of all hospitalizations require heparin; (4) market consolidation and discontinuations reducing the number of active U.S. suppliers; and (5) tariff pressure on Chinese pharmaceutical imports potentially increasing raw material costs and reducing economic viability for some manufacturers.

Clinical Implications and Prescribing Guidance

For inpatient settings, hospital pharmacies should be consulted regarding current formulary availability and preferred manufacturer. For outpatients, several clinical considerations apply:

Bridge therapy: For patients transitioning from warfarin pre- and post-procedure, consider whether an LMWH such as enoxaparin or dalteparin can be substituted. LMWH has a more predictable pharmacokinetic profile and does not require aPTT monitoring for most patients.

DVT/PE outpatient treatment: If UFH is unavailable, DOACs (rivaroxaban or apixaban) are appropriate first-line oral options for most hemodynamically stable patients without contraindications (renal impairment, pregnancy, mechanical valves).

Pregnancy: UFH and LMWH (enoxaparin, dalteparin) remain the only safe anticoagulants in pregnancy. DOACs and warfarin are contraindicated. If heparin is unavailable, enoxaparin is the preferred substitute — use preservative-free formulations and monitor anti-Xa levels.

HIT history: Avoid all heparin and LMWH products. Fondaparinux is the preferred injectable option. Argatroban or bivalirudin for inpatient IV management.

Mechanical heart valves: DOACs are contraindicated. If UFH is unavailable, warfarin with LMWH bridging or dalteparin may be considered on a case-by-case basis.

Monitoring and Safety Considerations

When heparin is administered in any form:

Monitor aPTT every 6 hours initially for IV heparin until therapeutic range (60-85 seconds) is achieved

Baseline and periodic platelet counts — thrombocytopenia developing 5-14 days after initiation should prompt HIT workup

Be alert to concentration errors — heparin is a high-alert medication with multiple concentrations; confirm the correct vial strength before administration

Inspect Pfizer Carpuject units for needle sheath integrity per the March 2026 Drug Warning Letter

37,598+ patients found their medications in stock

37K+

Find Heparin In Stock Today →

Tools to Help Your Outpatients Access Heparin

For outpatients struggling to fill heparin prescriptions, medfinder for providers enables your patients to have pharmacies near them checked for availability. This significantly reduces the burden on patients and your office staff fielding refill-access calls. For a practical workflow guide, see how to help your patients find heparin in stock.